Compare IMSR & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMSR | ESPR |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | 74 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.8M | 731.9M |
| IPO Year | N/A | 2013 |
| Metric | IMSR | ESPR |
|---|---|---|
| Price | $7.83 | $1.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 2.0M | ★ 7.4M |
| Earning Date | 05-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $5.33 | $0.73 |
| 52 Week High | $16.38 | $4.18 |
| Indicator | IMSR | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 31.41 |
| Support Level | $7.52 | $1.34 |
| Resistance Level | $11.04 | $2.08 |
| Average True Range (ATR) | 0.67 | 0.16 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 64.00 | 11.89 |
Terrestrial Energy Inc is a technology company engaged in the development and commercialization of nuclear power plants. The company is focused on its proprietary Integral Molten Salt Reactor (IMSR) technology, a Generation IV reactor design intended to produce reliable, emission-free energy in the form of electricity and high-temperature heat for industrial applications. Its activities mainly involve advancing the design, licensing, and deployment of IMSR plants for commercial energy generation.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.